[Podoplanin--a specific marker for lymphatic endothelium expressed in angiosarcoma]

Area of Science:

• Vascular biology and oncology
• Immunohistochemistry and molecular pathology
• Tumor marker development

Context:

• Angiosarcomas can originate from blood or lymphatic endothelia, but distinguishing these origins is challenging due to a lack of specific markers.
• Existing endothelial markers do not reliably differentiate between blood and lymphatic endothelial cells in complex vascular tumors.
• Understanding tumor cell origin is crucial for accurate diagnosis and treatment of vascular neoplasms.

Purpose:

• To investigate podoplanin as a specific immunohistochemical marker for lymphatic endothelium.
• To evaluate the expression of podoplanin in normal human tissues and various vascular tumors.
• To determine the utility of podoplanin in differentiating blood and lymphatic endothelial components within vascular tumors.

Summary:

• Podoplanin was identified as a specific marker for lymphatic endothelium in normal tissues, absent in blood vasculature.
• In vascular tumors, podoplanin expression varied: it was consistently found in Kaposi's sarcomas and benign lymphatic lesions.
• G3 angiosarcomas showed a spectrum of podoplanin expression, with most tumors containing a mix of podoplanin-positive (lymphatic) and podoplanin-negative (blood) endothelial cells.

Impact:

• Establishes podoplanin as a reliable diagnostic marker for lymphatic endothelium in pathological specimens.
• Provides a tool to quantify the lymphatic endothelial component in angiosarcomas, aiding in subtyping and understanding tumor heterogeneity.
• Improves the differential diagnosis of vascular tumors, particularly distinguishing between angiosarcomas and Kaposi's sarcomas.